Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
STATE NET® THOUGHT LEADERSHIP SERIES How Historic Adoption Rates Hold the Key to Forecasting Future Regulatory Action Just as state legislatures vary in their bill passage rates, some state agencies...
Judge Strikes Down Part of MD Digital Ad Tax Law A federal judge struck down a provision of Maryland’s first-in-the-nation digital advertising tax law that prohibited online companies from notifying...
NLRB Sues California to Block Labor Board Law The National Labor Relations Board has filed a lawsuit to block a new California law ( AB 288 ) empowering the state’s Public Employee Relations Board...
TX AG Sues Johnson & Johnson over Claimed Tylenol-Autism Link Texas Attorney General Ken Paxton (R) filed a lawsuit against Johnson & Johnson this week claiming the company hid the risks of Tylenol...
Over the past 47 years, seven states have enacted their own, state-level versions of the federal Community Reinvestment Act to ensure financial institutions within their jurisdictions are meeting the banking...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.